Pfizer and Tacere to Tackle HCV with RNAi Therapeutic
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 92 (Table of Contents)
Published: 8 Feb-2008
DOI: 10.3833/pdr.v2008.i92.224 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer signed a collaboration and license agreement with Tacere Pharmaceuticals for a novel RNAi-based therapeutic for the treatment of HCV worth over US$145...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS